Biotech bro

4.3K posts

Biotech bro banner
Biotech bro

Biotech bro

@biotech_bro

Passionate about biotech On a side quest to build healthcare apps

Katılım Mart 2020
55 Takip Edilen2.3K Takipçiler
Sabitlenmiş Tweet
Biotech bro
Biotech bro@biotech_bro·
When I first started my biotech investing podcast, I focused on just producing content before launching a "subscription service". Well in a similar way I want to use this year to build, build as many things as I reasonable can. Likely all of them will be failures, but through trial and error I hope to: 1. Get better at going from idea to product 2. Unlock learnings by doing and subsequently sharing them, etc. 3. Make money along the way
English
0
0
0
279
lada
lada@ladanuzhna·
OpenAI buying TBPN would be like BMS buying a theater company... Oh wait
lada tweet media
English
3
3
33
4.4K
Biotech bro
Biotech bro@biotech_bro·
@SynBio1 But what if raise money and make a dashboard showing this data 😂😂
English
0
0
1
36
Jake Wintermute 🧬/acc
Jake Wintermute 🧬/acc@SynBio1·
I've posted before that the tech ethos of "you can just do things" is coming for biotech, where it will come into conflict with the biopharma ethos of "trust the experts" This is what that looks like
Brian Armstrong@brian_armstrong

Some of the most underinvested areas in frontier biology that could accelerate civilizational progress: - Cheap, large-scale DNA synthesis (writing entire chromosomes or full organisms) - Real-time, non-destructive RNA sequencing in living cells - Highly accurate AI-powered polygenic scores for complex traits (disease risk, cognition, longevity) → enabling full genome design - Ultra-precise, multiplex genome editing (far beyond CRISPR) with minimal off-target effects, scalable across millions of cells - Safe, efficient, tissue-specific in vivo delivery systems - Safe and effective human germline engineering - Accelerated clinical trials via testing on decedents (with consent) - Next-gen human enhancement: muscle, cognition, mood — beyond GLP-1s - Ectogenesis / artificial wombs Who’s actually building in these areas? Drop names, companies, or researchers below 👇

English
4
0
34
3K
Brian Armstrong
Brian Armstrong@brian_armstrong·
Some of the most underinvested areas in frontier biology that could accelerate civilizational progress: - Cheap, large-scale DNA synthesis (writing entire chromosomes or full organisms) - Real-time, non-destructive RNA sequencing in living cells - Highly accurate AI-powered polygenic scores for complex traits (disease risk, cognition, longevity) → enabling full genome design - Ultra-precise, multiplex genome editing (far beyond CRISPR) with minimal off-target effects, scalable across millions of cells - Safe, efficient, tissue-specific in vivo delivery systems - Safe and effective human germline engineering - Accelerated clinical trials via testing on decedents (with consent) - Next-gen human enhancement: muscle, cognition, mood — beyond GLP-1s - Ectogenesis / artificial wombs Who’s actually building in these areas? Drop names, companies, or researchers below 👇
English
271
152
1.3K
107.9K
Max
Max@MaxxingDelusion·
Sevilla looks like it was built for people who know how to live
Max tweet mediaMax tweet mediaMax tweet mediaMax tweet media
English
178
1.6K
22.2K
994.6K
Biotech bro
Biotech bro@biotech_bro·
@A_May_MD @semodough It’s as if people don’t see the similar success that multiple different MOAs have had in other autoimmune skin disorders like psoriasis
English
0
0
0
376
Adam May
Adam May@A_May_MD·
@semodough We badly need non IL4/13/STAT6 pathway drugs badly (yes, these “different” MoAs are the SAME pathway). Idk why it has been (is) so incredibly hard to convince the market of this. Frustrating.
English
3
0
51
3.5K
dough
dough@semodough·
Wow @A_May_MD from $NKTR own market research concluded that the derm community is very receptive to using new MOAs • Despite reported cases of KS in Amlitelimab's trials, NKTR mgmt's conversations w/ docs at AAD26 reveal that ~50% still believe SNY should continue Amlitelimab development, further highlighting derm docs' willingness to try new MOAs IMHO BODES well for $NKTR $CRVS $APGE
English
3
4
51
8K
Biotech bro
Biotech bro@biotech_bro·
Nothing funnier to see people who have absolutely no understanding of biotech suddenly start claiming all this AI nonsense regarding how it’s going to change drug development and lead to new drugs in the next 12 months.
English
0
0
4
326
Matt Schwartz
Matt Schwartz@matt_is_nice·
NEXT UP: acquiring the clinical phenotypic data to predict treatment outcomes! we've been building a data moat in endoscopy that is going to power AI insights in IBD, celiac, colorectal cancer, pancreatic cancer, and more
Ejaaz@cryptopunk7213

fuck yes we’re getting claude designer drugs anthropic just bought an ai drug design company for $400M, soon claude will be able to: - identify your medical issue - design a drug to cure it. - experiment and manufacture the drug - deliver that drug to you pharmaceutical R&D is worth $250B alone. dario wants to automate all of it this means cheaper healthcare (and insurance!) + MORE EFFECTIVE treatments the team they acquired are beasts, particularly nathan frey… - he’s won awards for his work on protein sequencing + worked with NVIDIA on their bio AI efforts so now we have google deepmind and anthropic working on AI-powered drug treatment i give <5 years till we have cures for 90% of ailments

English
2
3
7
1.3K
Biotech bro
Biotech bro@biotech_bro·
@cryptopunk7213 Realistically it will probably be improvements in document generation to submit ind enabling studies, pivotal or registrational trial design, etc.
English
0
0
1
36
Ejaaz
Ejaaz@cryptopunk7213·
fuck yes we’re getting claude designer drugs anthropic just bought an ai drug design company for $400M, soon claude will be able to: - identify your medical issue - design a drug to cure it. - experiment and manufacture the drug - deliver that drug to you pharmaceutical R&D is worth $250B alone. dario wants to automate all of it this means cheaper healthcare (and insurance!) + MORE EFFECTIVE treatments the team they acquired are beasts, particularly nathan frey… - he’s won awards for his work on protein sequencing + worked with NVIDIA on their bio AI efforts so now we have google deepmind and anthropic working on AI-powered drug treatment i give <5 years till we have cures for 90% of ailments
Ejaaz tweet media
English
45
35
475
31K
Biotech bro
Biotech bro@biotech_bro·
@alexeyguzey You know this because you’re a reputable scientist who has been through the process?
English
1
0
4
230
Biotech bro
Biotech bro@biotech_bro·
Your EOBs explained in simply language. Find out what you were charged, how it compares to others in your area, and what can you do to reduce your bill! Mobile version incoming! true-cost-18506c4a13f6.herokuapp.com
Biotech bro tweet media
English
0
0
0
118
Biotech bro
Biotech bro@biotech_bro·
Finished and deployed the first workable version of True Cost. Focused on making it easier to understand the cost of your medical care, benchmark it with those of others in your area, and in the future negotiate price reductions for the caree you receive! true-cost-18506c4a13f6.herokuapp.com
English
0
0
0
220
Biotech bro
Biotech bro@biotech_bro·
@DutchRojas once again, solutions to the healthcare crisis wont be private sector only. You need regulatory reform! It can unlock a lot of the insights and value we are craving from LLMs in a way that is way cheaper.
English
0
0
0
526
Dutch Rojas
Dutch Rojas@DutchRojas·
The most funded healthcare startup of the decade built a better prior auth system. For the insurer.
English
5
3
72
7.7K
Samuel Hume
Samuel Hume@DrSamuelBHume·
The case for p53 reactivators in cancer The most mutated gene, with (still) no targeted therapies
Samuel Hume tweet media
English
11
17
167
14.7K
Biotech bro
Biotech bro@biotech_bro·
Low-resolution biomarker framework is such a good phrase! The truth is most translational research is often that, trying to find the next EGFR that can be targeted. It’s also not clear to me how AI will help solve for this issue if we are training it on these datasets that are hyper prioritizing low-resolution biomarkers especially if you can’t sense check hallucinations
English
0
0
2
86
Jia (Jenny) Liu MD PhD
Jia (Jenny) Liu MD PhD@JiaJennyLiu·
TIGIT showed us this: scale without biological precision is expensive noise. ADC trial activity is accelerating globally. But patient selection hasn’t evolved. We’re building a high-speed system on a low-resolution biomarker framework.
Jia (Jenny) Liu MD PhD tweet media
Jia (Jenny) Liu MD PhD@JiaJennyLiu

The TIGIT catastrophe‼️ 30 agents 220 trials ~50,000 patients >$3B+ invested 0 approvals. This is herding in drug development. In BMJ Oncol we examine why it happens, the hidden costs, and what needs to change. It’s already happening again in ADCs... 🔗:bmjoncology.bmj.com/content/5/1/e0…

English
5
10
59
8.2K
Biotech bro
Biotech bro@biotech_bro·
@draparente Don’t disagree. OPs is a great use case though I am curious how “useable” these tools are.
English
0
0
2
161
Angelica Parente
Angelica Parente@draparente·
While not flashy, I've been saying ops is the lowest hanging fruit for AI in biotech for a while.
NIK@ns123abc

BREAKING: Anthropic Acquires 9-Person Biotech Startup For $400 Million >be coefficient bio >founded the startup 6 months ago >build AI platform for biotech >less than 10 employees >acquired by anthropic for ~$400 million > = $40+ million per head Coefficient Bio was building an AI platform for biotech tasks: planning drug R&D, managing clinical regulatory strategy, identifying new drug opportunities Team is joining Anthropic’s healthcare life sciences group led by Eric Kauderer-Abrams. Anthropic is building specialized tools for industries that actually pay enterprise rates: >software engineering >cybersecurity >life sciences >healthcare >finance Meanwhile OpenAI is buying media companies to control narratives LMAO

English
4
1
33
10.2K

Keşfet

@ladanuzhna @Prof_Oak_ @SynBio1 @brian_armstrong @MaxxingDelusion @DKThomp @A_May_MD @semodough